Quintiles Library

Harnessing Vital Data Image
Featured White Paper

Harnessing vital data to inform an optimal market access strategy in the UK
Market access now demands closer collaboration between biopharma, payers and providers. In a climate where ongoing reimbursement of a drug relies on biopharma’s ability to demonstrate how it delivers value to the entire healthcare system, partnership working is essential. Outcomes audits should be seen as one of the most important tools available to biopharma. They deliver detailed action plans to both biopharma and the NHS, proposing improvements to the care pathway...
Show Filters
Presentation
There are two key elements in any successful strategy: knowing what to do, and knowing when to do it. Yet in terms of market access, there appears to be a lot of talk about the former, but not so much about the latter. There is no doubt that the processes and capabilities that pharma organizations need to employ have evolved. Since the creation of the UK's clinical commissioning groups (CCGs), the early development and implementation of a holistic market access solution based on local clinical and payer insight has become even more crucial. By watching the webinar, you will learn: How to clearly define a market access journey that brings together the right mix of activities What is the optimum time to begin engaging with stakeholders when implementing market access strategies ...
Explore More
Brochure
Creating a healthier world will require the industry’s best thinking and resources. It will also demand working together differently. Imagine a fully integrated approach that delivers biopharma and life sciences solutions from pipeline to portfolio to population health™.  At Quintiles, we’re connecting insights with superior delivery for better outcomes – all to make your goals a...
Read More
Brochure
Transforming early clinical development for better outcomes Greater investments of human and financial resources. More complex study designs. Earlier testing of drugs in patients. All of these are hallmarks of the current evolution in early clinical development. While the challenges are undeniable, they also provide the impetus to refine the development process into one that is smarter and more connected—and that offers a much improved return on your investment. Improve your probability of success Great opportunities await those drug developers who are positioned to seize them quickly. Quintiles’ scientific and medical expertise can help you make the strongest possible start, providing insights and high-precision data to inform better go/no-go decisions and arrive at a more robust proof...
Read more
Press Release
RESEARCH TRIANGLE PARK, N.C. – December 17, 2014 – Quintiles CEO Tom Pike will present at the 2015 J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015 in San Francisco at the Westin St. Francis Hotel. The Quintiles presentation will begin at 9:00 a.m. PST. Investors may access a live audio webcast of the presentation on the Quintiles’ Investor Relations website at www.quintiles.com/investors. An archived audio version of the presentation will be available later that day. About Quintiles Quintiles (NYSE: Q), a Fortune 500 company, is the world’s largest provider of biopharmaceutical development and commercial outsourcing services. With a network of more than 32,000 employees conducting business in approximately 100 countries, we helped develop or commercialize all of 2013’s...
Read More
Presentation
This webinar focuses on benefit-risk management and evaluation and managing evolving regulatory safety standards. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) are increasingly moving from a separate safety and effectiveness assessments model to combined benefit-risk assessments. Both the EMA and the FDA are making transparency a priority, proactively seeking the viewpoints of patients and other stakeholders, striving for optimum safety integration into the healthcare system and assessing a medication's real-world value by examining and optimizing its benefit-risk trade-offs in populations and sub-populations. This shift in approach provides challenges and opportunities in addressing these evolving requirements, as regulatory agencies increasingly...
Explore More
Video
Graham Clarke, PhD, Senior Director and Head of Respiratory & Inflammation, Quintiles Early Clinical Development - discusses the importance’s of Respiratory research and how Quintiles has developed the BioSPIT initiative, a study to harmonize methodologies across dedicated centers for multi-center trials using induced sputum as a primary outcome measure for asthma and COPD studies. This is the player to use for single videos on Q.com ...
Video
Oren Cohen, MD, Senior Vice President, Quintiles Early Clinical Development - discusses how Quintiles scientific and medical expertise can help customers get off to a better start, provide insights and high precision data to get to better go/no go decisions and to get to a more robust proof of concept. This is the player to use for single videos on Q.com ...
Video
Dr Richard Adams, Clinical Oncologist, Cardiff University, Wales, gives an overview of the use of biosimilars in oncology care. This is the player to use for single videos on Q.com ...
Video
Professor Ernest Choy, Head of Rheumatology and Translational Research, Cardiff University, Wales, explores the use of biosimilars in other approved indications. This is the player to use for single videos on Q.com ...
Video
Dr Richard Adams, Clinical Oncologist, Cardiff University, Wales, explains the importance of engaging patients in biosimilars trials. This is the player to use for single videos on Q.com ...
Video
Professor Ernest Choy, Head of Rheumatology and Translational Research, Cardiff University, Wales, discusses the use of biosimilars in rheumatoid arthritis. This is the player to use for single videos on Q.com ...
Press Release
SINGAPORE – December 9, 2014 – For the sixth time in eight years, Quintiles has been named Asia-Pacific Contract Research Organization of the Year by Frost & Sullivan, a leading business research and consulting firm. The award honors the CRO that scores the highest in Frost & Sullivan’s evaluation of several performance categories, including customer service; price/performance value; pioneering best practices; and addressing unmet needs. Frost & Sullivan cited Quintiles’ local market knowledge; its Asia-Pacific capabilities that complement its global offering; and its ability to provide solutions to meet customers’ most pressing needs as some of the reasons why Quintiles was selected as 2014 CRO of the Year. “I’d like to thank our 10,000 employees across Asia-Pacific for their efforts –...
Read More
Brochure
The growing complexity of central nervous system (CNS) indications – from Alzheimer’s to schizophrenia to epilepsy – highlights the need for safer, more cost-effective treatment options. Biopharmaceutical companies developing CNS therapies face a number of challenges, including poor medication compliance, the need for intensive care delivery and multiple caregivers, the heterogeneous trial population and a tough regulatory environment. To help you provide the evidence your stakeholders demand, Quintiles offers deep expertise and experience in real-world and late phase CNS research. We can effectively transition evidence development efforts from early phase research into Phase IIIB and post-approval studies, delivering high-quality data to help improve your products’ chance of success in...
Read More
Press Release
RESEARCH TRIANGLE PARK, N.C.  – December 4, 2014 – Quintiles today announced that the company was awarded “Best Contract Research Organization” at the annual SCRIP Awards for the third year in-a-row. This is the company’s fourth award received in this category in the last five years. The SCRIP Awards acknowledge excellence in the biopharmaceutical industry, based on judging by an independent panel of 12 life sciences experts. “Our judges felt Quintiles was a worthy winner of the Best Contract Research Organization trophy for the third year in a row,” said Mike Ward, global director of content for IBI Pharma News & Datamonitor Healthcare.  “In the qualifying year, Quintiles once again demonstrated a series of performance milestones in its quest to improve its customers' probability of...
Read More
Video
Kamali Chance, Head of Global Biosimilars Regulatory Strategy, Quintiles explains why sites should get involved in clinical trials for biosimilars. This is the player to use for single videos on Q.com ...
Video
John Doyle, Senior VP & Managing Director of Global Market Access Consulting at Quintiles, discusses the importance of biosimilars and how they influence market access. This is the player to use for single videos on Q.com ...
Video
Harish Dave, Global Head of Medical Strategy in Oncology at Quintiles, discusses the importance of biosimilars and how they influence standard of care. This is the player to use for single videos on Q.com ...
Video
Kamali Chance, Head of Global Biosimilars Regulatory Strategy at Quintiles, notes that all patients, regardless of what arm of the clinical trial they are in, will receive the active product and John Doyle, Senior VP & Managing Director of Global Market Access Consulting, Quintiles, describes how patients will gain the ability to have their opinions heard on the outcomes of research. This is the player to use for single videos on Q.com ...
Video
Peter Pitts, President of the Center of Medicine in the Public Interest, discusses the importance of biosimilars and how they influence innovation and regulation. This is the player to use for single videos on Q.com ...
Video
Kamali Chance, Head of Global Biosimilars Regulatory Strategy at Quintiles, explains why the clinical research and regulation of biosimilar medicines is far more rigorous than for small-molecule generic drugs. This is the player to use for single videos on Q.com ...